世界のプレガバリン市場 – 2031 年までの業界動向と予測

プレガバリン市場分析と規模

プレガバリンは、てんかん、神経障害性疼痛、線維筋痛症、全般性 不安障害の治療に使用できる抗けいれん薬です。体中の損傷した神経から伝わる痛みの信号を軽減することで効果を発揮します。国際疼痛学会の神経障害性疼痛撲滅のための世界年 2014-2015 調査によると、成人の約 7% ～ 8% が​​神経障害性の特徴を持つ慢性疼痛に苦しんでいます。

データブリッジマーケットリサーチは、2023年に8億2,475万米ドルだった世界のプレガバリン市場は、2031年までに10億8,856万米ドルに達する可能性があり、予測期間中に3.53％のCAGRを達成すると予測しています。プレガバリンの経口剤形の需要が高まっているため、「経口」が市場の剤形セグメントを支配しています。データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

プレガバリン市場の範囲とセグメンテーション

Market Definition

Pregabalin is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, and generalized anxiety disorder. It's an epilepsy medication that's used to treat partial seizures. It functions by lowering nerve activity and lowering pain. Anti-epileptic medicines (AEDs) such as Lyrica (pregabalin) and Topamax (topiramate) are used to prevent epileptic seizures. Lyrica is also indicated to treat diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia neuropathic pain.

Pregabalin Market Dynamics

Drivers

• Rise in the Prevalence of Epilepsy

The surging prevalence of epilepsy is a major factor driving the pregabalin market's growth rate during the forecast period. According to the World Health Organization (WHO), an estimated 50 million people are living with epilepsy globally in 2019, with up to 75 percent of them living in resource-poor countries with little or no access to treatment or medical services. Furthermore, approximately 80% of people with epilepsy live in low- and middle-income nations. In the treatment of epilepsy, pregabalin stops seizures by reducing aberrant electrical activity in the brain.

• Extensive application of Lyrica

The growing application of Lyrica is anticipated to propel the market's growth rate. Lyrica (pregabalin) is a fibromyalgia drug approved by the US Food and Drug Administration. Fibromyalgia is a chronic illness that causes long-term, widespread muscle pain and soreness and sleeping difficulties and exhaustion. Lyrica is a drug used to treat nerve signals. Fibromyalgia affects over 4 million individuals in the United States, or about 2% of the adult population, according to the Centers for Disease Control and Prevention (CDC). The etiology of fibromyalgia is unknown, but it can be effectively treated and managed. Lyrica has long been used to treat nerve pain in shingles or diabetic neuropathy patients. The drug Lyrica is also used to treat partial seizures.

• Rising geriatric population

Neuropathic pain and certain anxiety disorders are more prevalent in the elderly population. With a growing global aging demographic, there is an increased demand for medications that address age-related health issues. Pregabalin's effectiveness in managing pain and anxiety makes it a valuable option for this demographic, thereby driving market growth.

• Growing investment in healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Research and development for new indications

Investing in research and development to explore new therapeutic indications for pregabalin could open up new markets and revenue streams. Identifying and validating additional medical conditions where pregabalin demonstrates efficacy could lead to expanded usage and increased market share.

• Strategic collaborations and partnerships

Collaboration between pharmaceutical companies, research institutions, and healthcare providers can create synergies and drive market growth. Partnerships for clinical trials, marketing initiatives, or distribution agreements can enhance the visibility and accessibility of pregabalin, particularly in regions with unmet medical needs.

Restraints

• Generic competition and patent expiry

The expiration of patents for branded pregabalin products can lead to increased competition from generic manufacturers. Generic alternatives are typically more affordable, which can negatively impact the market share and revenue of the original drug.

• Side effects and safety concerns

Pregabalin, like any medication, may have side effects, and concerns about its safety profile could pose a restraint. As more information becomes available about potential side effects or adverse reactions, healthcare providers and patients may become more cautious in prescribing and using pregabalin.

Challenges

• Intense competition and market saturation

The pregablin market has become highly competitive with the presence of established companies and new entrants. The saturation of the market could pose challenges for companies in terms of differentiation, pricing, and market share.

• Cost containment pressures

Healthcare systems worldwide are under pressure to contain costs, and this can affect the pricing and reimbursement of pharmaceuticals, including pregabalin. Payers may push for lower prices, impacting the revenue potential for manufacturers. Navigating pricing negotiations and demonstrating the value proposition of pregabalin in terms of efficacy and patient outcomes can be challenging.

This pregabalin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pregabalin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In June 2023, Food and Drug Administration (FDA) approved SinoT’s ANDA application for PREGABALIN EXTENDED-RELEASE TABLETS 82.5 mg, 165 mg, and 330 mg for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN), and Postherpetic neuralgia (PHN)
• In April 2023, Pakistani pharmaceutical firm AGP Limited acquired a selected portfolio of products from American firm Viatris Inc. The portfolio includes many anti-depressants, including pregabalin, anti-hypertensive, and ophthalmology products

Global Pregabalin Market Scope

The pregabalin market is segmented on the basis of drug class, application, dosage forms, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Epilepsy
• Neuropathic Pain
• Anxiety Disorder
• Others

Drug Class

• Fibromyalgia Agents
• Anticonvulsants
• Others

Dosage Forms

• Oral Capsule
• 100 mg
• 150 mg
• 200 mg
• 225 mg
• 25 mg
• 300 mg
• 50 mg
• 75 mg
• Oral Solution
• 20 mg/mL
• Oral Tablet, extended release
• 165 mg
• 330 mg
• 82.5 mg

End-Users

• Hospitals

• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Pregabalin Market Regional Analysis/Insights

The pregabalin market is analyzed and market size insights and trends are provided by country, drug class, application, dosage forms, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the market due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. In addition, an increase in the number of research and development activities will further propel the market's growth rate in this region.

アジア太平洋地域は、この地域でのけいれんや不安障害の有病率が急増しているため、予測期間中に成長すると予想されています。また、医療インフラの発展と高齢者人口の増加により、この地域の市場の成長率がさらに加速するでしょう。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。   

ヘルスケアインフラの成長 導入ベースと新技術の浸透

プレガバリン市場では、各国の医療設備支出の増加、プレガバリン市場向け各種製品のインストールベース、ライフライン曲線を使用した技術の影響、医療規制シナリオの変化とそれらがプレガバリン市場に与える影響など、詳細な市場分析も提供しています。データは、2010年から2020年までの履歴期間について入手可能です。

競争環境と世界のプレガバリン市場シェア分析

プレガバリン市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、プレガバリン市場に関連する会社の焦点にのみ関連しています。

プレガバリン市場で活動している主要企業は次のとおりです。

• ファイザー社（米国）
• グラクソ・スミスクライン（英国）
• ノバルティスAG（スイス）
• マイランNV（米国）
• テバ製薬工業株式会社（イスラエル）
• サノフィ（フランス）
• F.ホフマン・ラ・ロシュ社（スイス）
• オーロビンドファーマ（インド）
• ルピナス（インド）
• ジダス・カディラ（インド）
• アムニール・ファーマシューティカルズLLC（米国）
• シプラ社（米国）
• トレント・ファーマシューティカルズ・リミテッド（インド）
• グレンマーク・ファーマシューティカルズ・リミテッド（インド）
• メドレー製薬株式会社（インド）
• ジェネシスバイオテック社（インド）
• バイオマックス製薬会社（英国）
• ZCLケミカルズ株式会社（インド）
• オロン SpA (イタリア)
• HIKAL Ltd.（インド）

SKU-58532